Market revenue in 2023 | USD 36.2 million |
Market revenue in 2030 | USD 81.7 million |
Growth rate | 12.3% (CAGR from 2023 to 2030) |
Largest segment | Endocrine signaling |
Fastest growing segment | Endocrine Signaling |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Endocrine Signaling, Paracrine Signaling, Autocrine Signaling |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Becton Dickinson & Co, Bio-Rad Laboratories Inc, Bio-Techne Corp, Cell Signaling Technology, Danaher Corp, Merck KGaA, PerkinElmer, Promega |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell signaling market will help companies and investors design strategic landscapes.
Endocrine signaling was the largest segment with a revenue share of 43.09% in 2023. Horizon Databook has segmented the UAE cell signaling market based on endocrine signaling, paracrine signaling, autocrine signaling covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE cell signaling market, including forecasts for subscribers. This country databook contains high-level insights into UAE cell signaling market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account